Pancreatic Adenocarcinoma and Trousseau's Syndrome

Clinical Presentation and Diagnosis

Pancreatic adenocarcinoma is the cancer most strongly associated with migratory thrombophlebitis (Trousseau's syndrome) in a middle-aged woman presenting with weight loss 1, 2
The combination of migratory thrombophlebitis and weight loss in this patient represents Trousseau's syndrome, a paraneoplastic phenomenon where recurrent superficial thrombophlebitis serves as a harbinger of underlying malignancy 1, 2
Trousseau's syndrome is characterized by warfarin resistance, thrombocytopenia, chronic disseminated intravascular coagulation, and requires treatment with unfractionated or low-molecular-weight heparin rather than warfarin 1, 2

Pancreatic cancer consistently ranks as one of the malignancies with the highest incidence of venous thromboembolism across multiple epidemiologic studies 3, 4, 5
The 1-year incidence rate of VTE in pancreatic cancer patients is 4-13 times higher in those with metastatic disease compared to localized disease 5
The early expression of tissue factor on preneoplastic and neoplastic pancreatic tissue drives the hypercoagulable state 3

A CT scan of the abdomen with contrast is recommended to evaluate for pancreatic mass, given the strong association and the presence of weight loss suggesting possible gastric outlet obstruction 3
CA19-9 tumor marker, though not diagnostic alone, can support the diagnosis when elevated 3
Initiate anticoagulation with low-molecular-weight heparin (not warfarin) immediately, as Trousseau's syndrome is notoriously warfarin-resistant 1, 2

Do not assume standard warfarin anticoagulation will be effective in this setting—Trousseau's syndrome requires heparin-based therapy (unfractionated heparin, low-molecular-weight heparin, or fondaparinux) for adequate thrombosis control 1, 2